Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01243944
Registration number
NCT01243944
Ethics application status
Date submitted
17/11/2010
Date registered
19/11/2010
Date last updated
6/03/2019
Titles & IDs
Public title
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
Query!
Scientific title
Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care (The RESPONSE Trial)
Query!
Secondary ID [1]
0
0
CINC424B2301
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Polycythemia Vera
0
0
Query!
Condition category
Condition code
Blood
0
0
0
0
Query!
Haematological diseases
Query!
Blood
0
0
0
0
Query!
Other blood disorders
Query!
Intervention/exposure
Study type
Interventional(has expanded access)
Query!
Description of intervention(s) / exposure
Treatment: Drugs - ruxolitinib tablets
Other interventions - Best Available Therapy (BAT)
Experimental: ruxolitinib tablets - Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg once a day (QD) to 25 mg BID based on safety and efficacy
Other: Best Available Therapy - Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
Treatment: Drugs: ruxolitinib tablets
Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy
Other interventions: Best Available Therapy (BAT)
Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
The Percentage of Participants Achieving a Primary Response at Week 32
Query!
Assessment method [1]
0
0
Primary response was defined as having achieved hematocrit control (the absence of phlebotomy eligibility beginning at the Week 8 visit and continuing through Week 32) and Spleen Volume Reduction (a greater than or equal to 35% reduction from baseline in spleen volume at Week 32).
Query!
Timepoint [1]
0
0
32 Weeks
Query!
Secondary outcome [1]
0
0
The Percentage of Participants Achieving a Durable Primary Response at Week 48
Query!
Assessment method [1]
0
0
Durable Primary Response was defined as any participant who achieved the primary outcome measure and who maintained their response up to 48 weeks after randomization.
Query!
Timepoint [1]
0
0
48 Weeks
Query!
Secondary outcome [2]
0
0
The Percentage of Participants Achieving Complete Hematological Remission at Week 32
Query!
Assessment method [2]
0
0
Complete Hematological Remission at Week 32 was defined as any participant who achieved hematocrit control with a platelet count less than or equal to 400 X 10\^9/L and a white blood cell count less than or equal to 10 X 10\^9/L.
Query!
Timepoint [2]
0
0
32 Weeks
Query!
Secondary outcome [3]
0
0
The Percentage of Participants Who Achieved a Durable Complete Hematological Remission at Week 48
Query!
Assessment method [3]
0
0
Durable Complete Hematological Remission was defined as any participant who achieved Complete Hematological Remission at Week 32 and maintained their response up to 48 weeks after randomization.
Query!
Timepoint [3]
0
0
48 Weeks
Query!
Secondary outcome [4]
0
0
The Percentage of Participants Who Achieved a Durable Hematocrit Control at Week 48
Query!
Assessment method [4]
0
0
Durable Hematocrit Control was defined as any participant who achieved phlebotomy eligibility independence from Week 8 to Week 32 and maintained hematocrit control up to 48 weeks after randomization.
Query!
Timepoint [4]
0
0
48 Weeks
Query!
Secondary outcome [5]
0
0
The Percentage of Participants Who Achieved Durable Spleen Volume Reduction at Week 48
Query!
Assessment method [5]
0
0
Durable Spleen Volume Reduction was defined as a participant who achieved at least 35% reduction from baseline in spleen volume at Week 32 and maintained that response 48 weeks after randomization.
Query!
Timepoint [5]
0
0
48 Weeks
Query!
Secondary outcome [6]
0
0
Estimated Duration of the Primary Response
Query!
Assessment method [6]
0
0
Duration of the primary response is defined as the time from the first occurrence when both components of the primary endpoint are met until the date of the first documented disease progression (end of response).
Kaplan-Meier estimates are provided for duration of primary response.
Query!
Timepoint [6]
0
0
Through study completion, analysis was conducted when all participants had completed the Week 80 visit or discontinued the study
Query!
Secondary outcome [7]
0
0
The Percentage of Participants Who Achieved Overall Clinicohematologic Response at Week 32
Query!
Assessment method [7]
0
0
Overall Clinicohematologic Response is defined as any participant who achieved a complete or partial clinicohematologic response per the European LeukemiaNet modified criteria for response in polycythemia vera (PV). A Complete Response (CR) is defined as: hematocrit control, spleen volume reduction at least 35% from baseline, platelet count less than or equal to 400 x 10(9)/L, and white blood cell count less than or equal to 10 x 10(9)/L. A Partial Response (PR) is defined as hematocrit control or response in all 3 of the other criteria.
Query!
Timepoint [7]
0
0
32 Weeks
Query!
Secondary outcome [8]
0
0
The Percentage of Participants Achieving a Durable Complete or Partial Clinicohematologic Response at Week 48
Query!
Assessment method [8]
0
0
Durable Complete or Partial Clinicohematologic Response was defined as any participant who achieved complete or partial clinicohematologic response per the European LeukemiaNet modified criteria for response in polycythemia vera at Week 32 and maintained that response 48 weeks after randomization.
Query!
Timepoint [8]
0
0
48 Weeks
Query!
Secondary outcome [9]
0
0
Estimated Duration of the Complete Hematological Remission
Query!
Assessment method [9]
0
0
Duration of the complete hematological remission is defined as the time from the first occurrence of complete hematological remission until the date of the first documented progression (end of response).
Kaplan-Meier estimates are provided for duration of complete hematological remission.
Query!
Timepoint [9]
0
0
Through study completion, analysis was conducted when all participants had completed the Week 80 visit or discontinued the study
Query!
Secondary outcome [10]
0
0
Duration of the Absence of Phlebotomy Eligibility
Query!
Assessment method [10]
0
0
Duration of the absence of phlebotomy eligibility is defined as the time from the first occurrence of absence of phlebotomy eligibility until the date of the first documented progression.
Query!
Timepoint [10]
0
0
256 Weeks
Query!
Secondary outcome [11]
0
0
Duration of Reduction in Spleen Volume
Query!
Assessment method [11]
0
0
Duration of spleen volume reduction is defined as the time from the first occurrence of a \>=35% reduction from baseline in spleen volume until the date of the first documented progression.
Query!
Timepoint [11]
0
0
256 Weeks
Query!
Secondary outcome [12]
0
0
Duration of The Overall Clinicohematologic Response
Query!
Assessment method [12]
0
0
Duration of the overall clinicohematologic response was defined as the time from the first occurrence of complete response (CR) or partial response (PR) until the date of the first documented disease progression.
Query!
Timepoint [12]
0
0
256 Weeks
Query!
Eligibility
Key inclusion criteria
* Participants diagnosed with PV for at least 24 weeks prior to screening according to the 2008 World Health Organization criteria
* Participants resistant to or intolerant of hydroxyurea
* Participants with a phlebotomy requirement
* Participants with splenomegaly (palpable or non-palpable) and a spleen volume, as measured by MRI (or CT in applicable participants ), of greater than or equal to 450 cubic centimeters
* Participants with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Women who are pregnant or nursing
* Participants with inadequate liver or renal function
* Participants with significant bacterial, fungal, parasitic, or viral infection requiring treatment
* Participants with an active malignancy within the past 5 years, excluding specific skin cancers
* Participants with known active hepatitis or HIV positivity
* Participants who have previously received treatment with a JAK inhibitor
* Participants being treated with any investigational agent
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
27/10/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
9/02/2018
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
222
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Brisbane
Query!
Recruitment hospital [2]
0
0
- Parkville
Query!
Recruitment hospital [3]
0
0
- Tweed Heads
Query!
Recruitment postcode(s) [1]
0
0
- Brisbane
Query!
Recruitment postcode(s) [2]
0
0
- Parkville
Query!
Recruitment postcode(s) [3]
0
0
- Tweed Heads
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Idaho
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Louisiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Maine
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Maryland
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Missouri
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Nebraska
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New Jersey
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
South Carolina
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Tennessee
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Texas
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Washington
Query!
Country [19]
0
0
Argentina
Query!
State/province [19]
0
0
Buenos Aires
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Antwerp
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Brugge
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Bruxelles
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Leuven
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Hamilton
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
Montreal
Query!
Country [26]
0
0
Canada
Query!
State/province [26]
0
0
Toronto
Query!
Country [27]
0
0
China
Query!
State/province [27]
0
0
Beijing
Query!
Country [28]
0
0
China
Query!
State/province [28]
0
0
Hangzhou
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Avignon
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Bayonne
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Brest
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Lille
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Nantes
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Paris
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Vandœuvre-lès-Nancy
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Aachen
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Berlin
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Bonn
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Freiburg
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Hamburg
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Jena
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Magdeburg
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Mannheim
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Minden
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Munchen
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Ulm
Query!
Country [47]
0
0
Hungary
Query!
State/province [47]
0
0
Budapest
Query!
Country [48]
0
0
Hungary
Query!
State/province [48]
0
0
Kecskemet
Query!
Country [49]
0
0
Hungary
Query!
State/province [49]
0
0
Szeged
Query!
Country [50]
0
0
Hungary
Query!
State/province [50]
0
0
Szombathely
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Bari
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Bergamo
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Bologna
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
Firenze
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Milano
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Napoli
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Orbassano
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Pavia
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Reggio Calabria
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Roma
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Varese
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Vicenza
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Chiba
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Chuo-city Yamanashi
Query!
Country [65]
0
0
Japan
Query!
State/province [65]
0
0
Maebashi
Query!
Country [66]
0
0
Japan
Query!
State/province [66]
0
0
Nagoya-city Aichi
Query!
Country [67]
0
0
Japan
Query!
State/province [67]
0
0
Osaka
Query!
Country [68]
0
0
Japan
Query!
State/province [68]
0
0
Tokyo
Query!
Country [69]
0
0
Korea, Republic of
Query!
State/province [69]
0
0
Seoul
Query!
Country [70]
0
0
Netherlands
Query!
State/province [70]
0
0
Enschede
Query!
Country [71]
0
0
Netherlands
Query!
State/province [71]
0
0
Rotterdam
Query!
Country [72]
0
0
Russian Federation
Query!
State/province [72]
0
0
Moscow
Query!
Country [73]
0
0
Russian Federation
Query!
State/province [73]
0
0
St. Petersburg
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Barcelona
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Coruña
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Las Palmas de Gran Canaria
Query!
Country [77]
0
0
Spain
Query!
State/province [77]
0
0
Madrid
Query!
Country [78]
0
0
Spain
Query!
State/province [78]
0
0
Majadahonda
Query!
Country [79]
0
0
Spain
Query!
State/province [79]
0
0
Malaga
Query!
Country [80]
0
0
Spain
Query!
State/province [80]
0
0
Pamplona
Query!
Country [81]
0
0
Spain
Query!
State/province [81]
0
0
Salamanca
Query!
Country [82]
0
0
Spain
Query!
State/province [82]
0
0
Valencia
Query!
Country [83]
0
0
Thailand
Query!
State/province [83]
0
0
Bangkok
Query!
Country [84]
0
0
Turkey
Query!
State/province [84]
0
0
Ankara
Query!
Country [85]
0
0
Turkey
Query!
State/province [85]
0
0
Istanbul
Query!
Country [86]
0
0
Turkey
Query!
State/province [86]
0
0
Izmir
Query!
Country [87]
0
0
United Kingdom
Query!
State/province [87]
0
0
Bournemouth
Query!
Country [88]
0
0
United Kingdom
Query!
State/province [88]
0
0
Cardiff
Query!
Country [89]
0
0
United Kingdom
Query!
State/province [89]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Incyte Corporation
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Novartis Pharmaceuticals
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This pivotal phase III trial (CINC424B2301) is designed to compare the efficacy and safety of ruxolitinib (INC424) to Best Available Therapy (BAT) in participants with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea (HU).
Query!
Trial website
https://clinicaltrials.gov/study/NCT01243944
Query!
Trial related presentations / publications
Kiladjian JJ, Zachee P, Hino M, Pane F, Masszi T, Harrison CN, Mesa R, Miller CB, Passamonti F, Durrant S, Griesshammer M, Kirito K, Besses C, Moiraghi B, Rumi E, Rosti V, Blau IW, Francillard N, Dong T, Wroclawska M, Vannucchi AM, Verstovsek S. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol. 2020 Mar;7(3):e226-e237. doi: 10.1016/S2352-3026(19)30207-8. Epub 2020 Jan 23. Kiladjian JJ, Guglielmelli P, Griesshammer M, Saydam G, Masszi T, Durrant S, Passamonti F, Jones M, Zhen H, Li J, Gadbaw B, Perez Ronco J, Khan M, Verstovsek S. Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. Ann Hematol. 2018 Apr;97(4):617-627. doi: 10.1007/s00277-017-3225-1. Epub 2018 Feb 2. Verstovsek S, Harrison CN, Kiladjian JJ, Miller C, Naim AB, Paranagama DC, Habr D, Vannucchi AM. Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. Leuk Res. 2017 May;56:52-59. doi: 10.1016/j.leukres.2017.01.032. Epub 2017 Jan 31. Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Kirito K, Besses C, Hino M, Moiraghi B, Miller CB, Cazzola M, Rosti V, Blau I, Mesa R, Jones MM, Zhen H, Li J, Francillard N, Habr D, Kiladjian JJ. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica. 2016 Jul;101(7):821-9. doi: 10.3324/haematol.2016.143644. Epub 2016 Apr 21. Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015 Jan 29;372(5):426-35. doi: 10.1056/NEJMoa1409002.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Srdan Verstovsek, MD,PhD
Query!
Address
0
0
M.D. Anderson Cancer Center
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01243944
Download to PDF